Results 31 to 40 of about 4,014 (178)

Efficacy and Safety of Generic (Velpatasvir containing regimen) among Adult Chronic HCV Patients Non-responders to Treatment by Sofosbuvir Plus Daclatasvir Regimen in Egypt [PDF]

Delta Journal of Science, 2023
Hepatitis C is caused by the hepatitis C virus. Various treatments for hepatitis C were ineffective before the use of direct-acting antivirals (DAAs). DAA has few (negative) adverse effects and high sustained virologic response rate (SVR12).
wessam ragab, Eman Fares, Heba Eldash, Naglaa Ismael, Ahmed Gomaa   +4 more
doaj   +1 more source

Impact of list price changes on out-of-pocket costs and adherence in four high-rebate specialty drugs

PLoS ONE, 2023
Background Insurers manage the cost of specialty medicines via rebates, however it is unclear if the savings are passed on to patients, and whether reducing rebates may lead to changes in patient out-of-pocket (OOP) costs and medication adherence.
William Bruce Wong, Arpamas Seetasith, Anna Hung, Leah L. Zullig   +3 more
doaj   +3 more sources

ANALYTICAL METHOD DEVELOPMENT AND VALIDATION FOR THE SIMULTANEOUS ESTIMATION OF SOFOSBUVIR AND VELPATASVIR DRUG PRODUCT BY REVERSE PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY METHOD [PDF]

, 2018
 Objectives: The purpose of the research is to develop a simple, precise, economical, accurate, reproducible, and sensitive method for the estimation of sofosbuvir and velpatasvir drug product by rp-hplc methodMethods: New Analytical method was ...
D, Ramachandran, Nekkala, Kalpana, J V, Shanmukha Kumar   +2 more
core   +3 more sources

Direct Acting Antivirals Which Is Effective in Pan-genotypic Chronic Hepatitis C Patients with or without Liver Cirrhosis

The Korean Journal of Gastroenterology, 2016
Articles: Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection (N Engl J Med 2015;373:2599-2607) Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection (N Engl J Med 2015;373:2608-2617)
Ki Tae Yoon
doaj   +1 more source

Combination of Direct Antiviral Therapy in Hepatitis C Patients, Population of Karachi

Pakistan Journal of Medicine and Dentistry, 2020
Background: Pakistan has approximately eight million Hepatitis C Virus (HCV) infected patients. Initial regimen of interferon-based along with ribavirin showed SVR (Sustained Virological Response Rate) of up to 50%.
Samia Perwaiz Khan, Muslim Abbas, Ajeet Kumar, Fadieleh A. Sohail, Rubina Ghani   +4 more
doaj   +1 more source

Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection [PDF]

, 2015
BACKGROUND: A simple treatment regimen that is effective in a broad range of patients who are chronically infected with the hepatitis C virus (HCV) remains an unmet medical need.
Moreno, C, Feld, JJ, Asselah, T, Mangia, A, McHutchison, JG, Yoshida, E, Zeuzem, S, Ruane, PJ, Lai, CL, Jacobson, IM, Agarwal, K, Tran, TT, Mazzotta, F, Abergel, A, Gruener, N, Towner, WJ, Osinusi, A, Hézode, C, Shafran, SD, McNally, J, Zhu, Y, Chan, HLY, Svarovskaia, E, Brainard, DM   +23 more
core   +1 more source

Safety and efficacy of sofosbuvir plus velpatasvir with or without ribavirin for chronic hepatitis C virus infection: A systematic review and meta-analysis

Journal of Infection and Public Health, 2018
Velpatasvir is a newly FDA-approved inhibitor of hepatitis C virus (HCV) NS5A protein. We performed this systematic review and meta-analysis to investigate the safety and efficacy of velpatasvir plus sofosbuvir in the treatment of chronic HCV infection ...
Hussien Ahmed, Abdelrahman I. Abushouk, Attia Attia, Mohamed Gadelkarim, Mohamed Gabr, Ahmed Negida, Mohamed M. Abdel-Daim   +6 more
doaj   +1 more source

Price of a hepatitis C cure: Cost of production and current prices for direct-acting antivirals in 50 countries

Journal of Virus Eradication, 2020
Objectives: Seven years after the introduction of direct-acting antivirals (DAAs) for the treatment of hepatitis C, high prices remain a barrier for treatment programs worldwide.
Melissa J. Barber, Dzintars Gotham, Giten Khwairakpam, Andrew Hill   +3 more
doaj   +1 more source

Use of glecaprevir and pibrentasvir as rescue therapy in patients with resistance to direct-acting antiviral agents

Annals of Hepatology, 2022
Introduction and Objective: Hepatitis C virus infection is one of the main causes of chronic liver disease. Treatment with direct-acting antivirals (DAAs) has shown high efficacy in achieving sustained viral response with a low risk of relapse. There are
LS Juarez Chavez, JS Sandoval Mendoza
doaj   +1 more source

Sofosbuvir/velpatasvir for 12 vs. 6 weeks for the treatment of recently acquired hepatitis C infection. [PDF]

, 2021
BACKGROUND AND AIMS Shortened duration therapy for acute and recent hepatitis C virus (HCV) infection has been shown to be highly effective in several small non-randomised studies with direct-acting antiviral regimens, however large randomised studies
Marks, Phillipa, Hellard, Margaret, Rockstroh, Juergen, Martinello, Marianne, Matthews, Gail V, Dore, Gregory J, Ingiliz, Patrick, Rockstroh, Jürgen, Petoumenos, Kathy, Feld, Jordan J, Thurnheer, Christine, Feld, Jordan, Bhagani, Sanjay, Bruneau, Julie, Van der Valk, Marc, Kim, Arthur, Marks, Pip, Applegate, Tanya, Rauch, Andri, Gane, Ed, Grebely, Jason, Shaw, David, Applegate, Tanya L, Dore, Greg, Matthews, Gail, Nelson, Mark, David Shaw, Christine Thurnheer, Sophia Amjad, Gail Matthews, Tanya L. Applegate, Dominique Braun, Maria Christine Thurnheer, Andrew Ustianowski, Julie Bruneau, Chris Fraser, Jordan J. Feld, Phillipa Marks, Arthur Y. Kim, Tanya Applegate, Andri Rauch, Thomas Lutz, Mark Hull, Mahshid Tamaddoni, Juergen Rockstroh, Yvonne Gilleece, Jürgen Rockstroh, Margaret Hellard, Phillip Read, Pip Marks, Marianne Martinello, Mark Nelson, Gail V. Matthews, Jordan Feld, Joe Sasadeusz, Greg Dore, Sanjay Bhagani, Patrick Ingiliz, Juhi Moon, Arthur Kim, Ed Gane, Kathy Petoumenos, Elise Tu, Christiane Cordes, Jason Grebely, Alberto Moriggia, Gregory J. Dore, Marc Van der Valk   +67 more
core   +2 more sources